Lixte Biotechnology (LIXT) News Today $4.29 +0.14 (+3.37%) Closing price 04:00 PM EasternExtended Trading$4.08 -0.22 (-5.01%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Lixte Biotechnology Regains Nasdaq Compliance After FundraisingJuly 19, 2025 | theglobeandmail.comLIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing RequirementsJuly 16, 2025 | globenewswire.comSpartan Capital Securities, LLC Serves as Placement Agent in Lixte ...July 11, 2025 | morningstar.comMSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $5.0 Million Private Placement | MorningstarJuly 9, 2025 | morningstar.comMLixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering | MorningstarJuly 9, 2025 | morningstar.comMLixte Biotechnology raises $1.5 million in registered direct offeringJuly 9, 2025 | investing.comSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct OfferingJuly 9, 2025 | finance.yahoo.comSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct OfferingJuly 9, 2025 | globenewswire.comNew Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer TrialsJuly 9, 2025 | globenewswire.comLixte Biotechnology Closes $1.5M Direct OfferingJuly 8, 2025 | tipranks.comLixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct OfferingJuly 8, 2025 | finance.yahoo.comSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private PlacementJuly 8, 2025 | globenewswire.comWall Street Today: S&P 500, Nasdaq rise as job data exceeds market expectations amid Trump tariff concernsJuly 4, 2025 | msn.comLixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market | MorningstarJuly 4, 2025 | morningstar.comMLixte Biotechnology (NASDAQ:LIXT) Stock, Insider Trading ActivityJuly 3, 2025 | benzinga.comLixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market | MorningstarJuly 2, 2025 | morningstar.comMLixte Biotechnology secures $5 million in private placementJuly 2, 2025 | investing.comLixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the MarketJuly 2, 2025 | globenewswire.comLixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the MarketJuly 1, 2025 | globenewswire.comLixte Biotechnology Converts Preferred Stock to CommonMay 20, 2025 | tipranks.comLixte Biotechnology files to sell 467,393 shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comLixte Biotechnology launches new study in collaboration with NKI on LB-100April 1, 2025 | markets.businessinsider.comLIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100March 31, 2025 | globenewswire.comLIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer TrialsMarch 29, 2025 | nasdaq.comLIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer - MorningstarMarch 29, 2025 | morningstar.comMLIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal CancerMarch 27, 2025 | globenewswire.comNew Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active FormMarch 10, 2025 | markets.businessinsider.comLixte announces online publication of new pre-clinical data in BioXrivMarch 10, 2025 | markets.businessinsider.comLIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell CancerFebruary 25, 2025 | markets.businessinsider.comLIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell CancerFebruary 25, 2025 | globenewswire.comLixte Biotechnology Holdings IncFebruary 15, 2025 | morningstar.comMLIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 13, 2025 | globenewswire.comLixte to sell 434,784 shares at $2.415 in registered direct offeringFebruary 11, 2025 | markets.businessinsider.comLIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 11, 2025 | globenewswire.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration StatementFebruary 11, 2025 | finanznachrichten.deLixte Biotechnology requests withdrawal of registration statementFebruary 11, 2025 | markets.businessinsider.comLIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration StatementFebruary 10, 2025 | globenewswire.comMercantile Bank (NASDAQ:MBWM) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comStryve Foods (NASDAQ:SNAX) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comLIXTE Receives U.S. Patent Issue Notification for Immune OncologySeptember 4, 2024 | globenewswire.comFirst Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 26, 2024 | finance.yahoo.comFirst Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 26, 2024 | globenewswire.comLIXTE Biotechnology Provides Update On Recent Activities and DevelopmentsAugust 19, 2024 | globenewswire.comLIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024August 16, 2024 | investorplace.comLIXTE Biotechnology Holdings to Present at Two Investor ConferencesAugust 15, 2024 | globenewswire.comLIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialJune 14, 2024 | globenewswire.comLIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialJune 14, 2024 | globenewswire.comScientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemJune 6, 2024 | globenewswire.comLIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerJune 3, 2024 | globenewswire.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Provides Update on Recent ActivitiesMay 20, 2024 | finanznachrichten.de Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address LIXT Media Mentions By Week LIXT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIXT News Sentiment▼0.000.63▲Average Medical News Sentiment LIXT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIXT Articles This Week▼10▲LIXT Articles Average Week Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MURA News LTRN News ACRV News MDCX News CALC News PLUR News CGTX News OVID News STTK News COEP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIXT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
